348 related articles for article (PubMed ID: 31495952)
1. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
Kocoshis SA; Merritt RJ; Hill S; Protheroe S; Carter BA; Horslen S; Hu S; Kaufman SS; Mercer DF; Pakarinen MP; Venick RS; Wales PW; Grimm AA
JPEN J Parenter Enteral Nutr; 2020 May; 44(4):621-631. PubMed ID: 31495952
[TBL] [Abstract][Full Text] [Related]
2. Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.
Seidner DL; Fujioka K; Boullata JI; Iyer K; Lee HM; Ziegler TR
Nutr Clin Pract; 2018 Aug; 33(4):520-527. PubMed ID: 29761915
[TBL] [Abstract][Full Text] [Related]
3. Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
Iyer KR; Kunecki M; Boullata JI; Fujioka K; Joly F; Gabe S; Pape UF; Schneider SM; Virgili Casas MN; Ziegler TR; Li B; Youssef NN; Jeppesen PB
JPEN J Parenter Enteral Nutr; 2017 Aug; 41(6):946-951. PubMed ID: 27875291
[TBL] [Abstract][Full Text] [Related]
4. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.
Ukleja A; To C; Alvarez A; Lara LF
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):821-825. PubMed ID: 29603279
[TBL] [Abstract][Full Text] [Related]
6. Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.
Seidner DL; Gabe SM; Lee HM; Olivier C; Jeppesen PB
JPEN J Parenter Enteral Nutr; 2020 May; 44(4):697-702. PubMed ID: 31423614
[TBL] [Abstract][Full Text] [Related]
7. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
Carter BA; Cohran VC; Cole CR; Corkins MR; Dimmitt RA; Duggan C; Hill S; Horslen S; Lim JD; Mercer DF; Merritt RJ; Nichol PF; Sigurdsson L; Teitelbaum DH; Thompson J; Vanderpool C; Vaughan JF; Li B; Youssef NN; Venick RS; Kocoshis SA
J Pediatr; 2017 Feb; 181():102-111.e5. PubMed ID: 27855998
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
[TBL] [Abstract][Full Text] [Related]
9. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
Chiba M; Masumoto K; Kaji T; Matsuura T; Morii M; Fagbemi A; Hill S; Pakarinen MP; Protheroe S; Urs A; Chen ST; Sakui S; Udagawa E; Wada M
J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):339-346. PubMed ID: 37364133
[TBL] [Abstract][Full Text] [Related]
11. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.
Chen K; Mu F; Xie J; Kelkar SS; Olivier C; Signorovitch J; Jeppesen PB
JPEN J Parenter Enteral Nutr; 2020 Jan; 44(1):119-128. PubMed ID: 31006876
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
[TBL] [Abstract][Full Text] [Related]
13. Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.
Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
Clin Nutr; 2020 Aug; 39(8):2479-2486. PubMed ID: 31784300
[TBL] [Abstract][Full Text] [Related]
14. Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.
Joly F; Seguy D; Nuzzo A; Chambrier C; Beau P; Poullenot F; Thibault R; Armengol Debeir L; Layec S; Boehm V; Lallemand J; Quilliot D; Schneider SM
Clin Nutr; 2020 Sep; 39(9):2856-2862. PubMed ID: 31932048
[TBL] [Abstract][Full Text] [Related]
15. Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.
Micic D; Robinson I; Kidd T; Terreri B; Raphael BP
Nutr Clin Pract; 2024 Jun; 39(3):634-640. PubMed ID: 38491966
[TBL] [Abstract][Full Text] [Related]
16. Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
Hill S; Carter BA; Cohran V; Horslen S; Kaufman SS; Kocoshis SA; Mercer DF; Merritt RJ; Pakarinen MP; Protheroe S; Thompson JF; Vanderpool CPB; Venick RS; Wales PW; Smith SE; Yoon M; Grimm AA
JPEN J Parenter Enteral Nutr; 2021 Sep; 45(7):1456-1465. PubMed ID: 33305440
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
O'Keefe SJ; Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):815-23.e1-3. PubMed ID: 23333663
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.
Nakamura S; Wada M; Mizushima T; Sugita A; Tazuke Y; Ohge H; Udagawa E; Suzuki RK; Yoon M; Grimm A; Chen ST; Ikeuchi H
Surg Today; 2023 Mar; 53(3):347-359. PubMed ID: 36201060
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.
Lambe C; Talbotec C; Kapel N; Barbot-Trystram L; Brabant S; Nader EA; Pigneur B; Payen E; Goulet O
Am J Clin Nutr; 2023 Jun; 117(6):1152-1163. PubMed ID: 37270289
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
Kochar B; Long MD; Shelton E; Young L; Farraye FA; Yajnik V; Herfarth H
J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
